A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1436 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-08

Study Completion Date

2017-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

NCT02949011

Influenza

COMPLETED PHASE3

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

NCT03684044

Influenza

COMPLETED PHASE3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

NCT03629184

Influenza

COMPLETED PHASE3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms

NCT06774859

Influenza

COMPLETED PHASE3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

NCT03653364

Influenza

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults: Baloxavir Marboxil

Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.

Group Type EXPERIMENTAL

Baloxavir Marboxil

Intervention Type DRUG

2 to4 X 20-mg tablets taken orally

Placebo to Oseltamivir

Intervention Type DRUG

Placebo capsules matching oseltamivir 75 mg capsules

Adults: Oseltamivir

Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.

Group Type ACTIVE_COMPARATOR

Placebo to Baloxavir Marboxil

Intervention Type DRUG

2 to4 X 20-mg tablets taken orally

Oseltamivir

Intervention Type DRUG

75 mg capsules taken orally

Adults: Placebo

Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.

Group Type PLACEBO_COMPARATOR

Placebo to Baloxavir Marboxil

Intervention Type DRUG

2 to4 X 20-mg tablets taken orally

Placebo to Oseltamivir

Intervention Type DRUG

Placebo capsules matching oseltamivir 75 mg capsules

Adolescents: Baloxavir Marboxil

Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.

Group Type EXPERIMENTAL

Baloxavir Marboxil

Intervention Type DRUG

2 to4 X 20-mg tablets taken orally

Adolescents: Placebo

Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.

Group Type PLACEBO_COMPARATOR

Placebo to Baloxavir Marboxil

Intervention Type DRUG

2 to4 X 20-mg tablets taken orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baloxavir Marboxil

2 to4 X 20-mg tablets taken orally

Intervention Type DRUG

Placebo to Baloxavir Marboxil

2 to4 X 20-mg tablets taken orally

Intervention Type DRUG

Oseltamivir

75 mg capsules taken orally

Intervention Type DRUG

Placebo to Oseltamivir

Placebo capsules matching oseltamivir 75 mg capsules

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

S-033188 Tamiflu®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who are able to understand the study and comply with all study procedures, and willing to provide written informed consent/assent prior to the predose examinations appropriately. As for adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements
2. Male or female patients aged ≥ 12 to ≤ 64 years at the time of signing the informed consent/assent form.
3. Patients with a diagnosis of influenza virus infection confirmed by all of the following:

1. Fever ≥ 38ºC (axillary) in the predose examinations or \> 4 hours after dosing of antipyretics if they were taken
2. At least one of the following general systemic symptoms associated with influenza are present with a severity of moderate or greater

* Headache
* Feverishness or chills
* Muscle or joint pain
* Fatigue
3. At least one of the following respiratory symptoms associated with influenza are present with a severity of moderate or greater

* Cough
* Sore throat
* Nasal congestion
4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:

1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
2. Time when the patient experiences at least one general or respiratory symptom
5. Women of childbearing potential who agree to use a highly effective method of contraception for 3 months after the first dose of study drug

Exclusion Criteria

1. Patients with severe influenza virus infection requiring inpatient treatment.
2. Patients aged ≥ 20 years with known allergy to oseltamivir (Tamiflu®).
3. Patients with any of the following risk factors

1. Women who are pregnant or within 2 weeks post-partum
2. Residents of long-term care facilities (eg, welfare facilities for the elderly, nursing homes)
3. Chronic respiratory diseases including bronchial asthma
4. Neurological and neurodevelopmental disorders including disorders of the brain, spinal cord, peripheral nerve, and muscle (eg, cerebral palsy, epilepsy \[seizure disorders\], stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
5. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms)
6. American Indians and Alaskan natives
7. Blood disorders (such as sickle cell disease)
8. Endocrine disorders (including diabetes mellitus)
9. Kidney disorders
10. Liver disorders
11. Metabolic disorders
12. Compromised immune system (including patients receiving immunosuppressant therapy, or those with cancer or human immunodeficiency virus \[HIV\] infection)
13. Morbid obesity (body mass index \[BMI\] ≥ 40)
4. Patients unable to swallow tablets or capsules.
5. Patients who have previously received Baloxavir Marboxil.
6. Patients weighing \< 40 kg
7. Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
8. Women who are breastfeeding or have a positive pregnancy test in the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test in the predose examinations:

1. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test) women
2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
9. Patients with concurrent infections requiring systemic antimicrobial and/or antiviral therapy at the predose examinations.
10. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, or amantadine within 30 days prior to the predose examinations.
11. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
12. Patients with severe underlying diseases.
13. Patients with known creatinine clearance ≤ 60 mL/min.
14. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions

Minimum Eligible Age

12 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No